Patents by Inventor Ruowei MO

Ruowei MO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250092036
    Abstract: The invention relates to compounds which modulate the activity of ERK. The present invention also relates to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by ERK.
    Type: Application
    Filed: August 12, 2024
    Publication date: March 20, 2025
    Inventors: Erich W. BAUM, Thomas A. DINEEN, JR., Jonathan Edward HEMPEL, Matthew James HESSE, Robert KOENIG, Matthew James LAMARCHE, Jay Francis LARROW, Ruowei MO, Henrik MOEBITZ, Rukundo NTAGANDA, Keith Bruce PFISTER, Martin SENDZIK, Colin Keith SKEPPER, Joseph WZOREK, JR., Frédéric ZECRI
  • Patent number: 11530213
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: December 20, 2022
    Assignee: Novartis AG
    Inventors: Guillaume Barbe, Gregory Raymond Bebernitz, Sicong Geng, Hatice Belgin Gulgeze Efthymiou, Lv Liao, Fupeng Ma, Ruowei Mo, David Thomas Parker, Yunshan Peng, Stefan Peukert, Nichola Smith, Ken Yamada, Kayo Yasoshima
  • Publication number: 20210284635
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: October 15, 2020
    Publication date: September 16, 2021
    Inventors: Guillaume BARBE, Gregory Raymond BEBERNITZ, Sicong GENG, Hatice Belgin GULGEZE EFTHYMIOU, Lv LIAO, Fupeng MA, Ruowei MO, David Thomas PARKER, Yunshan PENG, Stefan PEUKERT, Nichola Smith, Ken YAMADA, Kayo YASOSHIMA
  • Patent number: 10844055
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: November 24, 2020
    Assignee: NOVARTIS AG
    Inventors: Guillaume Barbe, Gregory Raymond Bebernitz, Sicong Geng, Hatice Belgin Gulgeze Efthymiou, Lv Liao, Fupeng Ma, Ruowei Mo, David Thomas Parker, Yunshan Peng, Stefan Peukert, Ken Yamada, Kayo Yasoshima, Nichola Smith
  • Publication number: 20190263803
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: March 1, 2019
    Publication date: August 29, 2019
    Inventors: Guillaume BARBE, Gregory Raymond BEBERNITZ, Sicong GENG, Hatice Belgin GULGEZE EFTHYMIOU, Lv LIAO, Fupeng MA, Ruowei MO, David Thomas PARKER, Yunshan PENG, Stefan PEUKERT, Ken YAMADA, Kayo YASOSHIMA
  • Patent number: 10266531
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: April 23, 2019
    Assignee: Novartis AG
    Inventors: Guillaume Barbe, Gregory Raymond Bebernitz, Sicong Geng, Hatice Belgin Gulgeze Efthymiou, Lv Liao, Fupeng Ma, Ruowei Mo, David Thomas Parker, Yunshan Peng, Stefan Peukert, Ken Yamada, Kayo Yasoshima
  • Publication number: 20180111932
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: October 19, 2017
    Publication date: April 26, 2018
    Inventors: Guillaume BARBE, Gregory Raymond BEBERNITZ, Sicong GENG, Hatice Belgin GULGEZE EFTHYMIOU, Lv LIAO, Fupeng MA, Ruowei MO, David Thomas PARKER, Yunshan PENG, Stefan PEUKERT, Ken YAMADA, Kayo YASOSHIMA